Sermorelin Global Regulatory Status: FDA History, Label Requirements, and Safety Record

What Is Sermorelin and Why Does Its Regulatory History Matter?

Sermorelin acetate is a synthetic 29-amino-acid analog of endogenous growth-hormone-releasing hormone (GHRH). It stimulates the pituitary gland to secrete growth hormone through the same receptor pathway as native GHRH. Because the pituitary remains in control of the pulse, sermorelin produces a more physiologic GH release pattern than direct recombinant GH injection.

Understanding its regulatory history matters for prescribers, compounding pharmacists, and patients alike. The drug has a single narrow FDA-approved indication that no longer has a commercially available product. Every prescription written today for sermorelin in adults or for anti-aging purposes falls outside that approved indication and depends entirely on the 503A compounding framework.

The Core Chemical and Pharmacological Profile

Sermorelin is the acetate salt of the 29-amino-acid N-terminal fragment of human GHRH. The molecular formula is C₁₄₉H₂₄₆N₄₄O₄₂S·xC₂H₄O₂. It binds the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary, triggering cyclic AMP-mediated GH release. Half-life after subcutaneous injection runs approximately 10 to 20 minutes, which is why nightly dosing is used clinically to mimic endogenous pulsatile secretion.

Why Pituitary Stimulation Differs from Direct GH Therapy

Because sermorelin works upstream of GH itself, the pituitary retains negative-feedback control via somatostatin. This physiologic brake is absent with direct recombinant human GH (rhGH) administration. That mechanistic difference underlies many of the safety arguments made in favor of sermorelin, and it also shaped how FDA reviewed the drug during its original NDA process.

FDA Approval: NDA 020613 and the Geref Era (1990 to 2008)

The FDA approved sermorelin acetate (brand name Geref, Serono Laboratories) on August 29, 1997, under NDA 020613. The single approved indication was: "for the treatment of idiopathic growth hormone deficiency in children with growth failure." [1]

The key safety and efficacy data supporting approval included the pediatric trial published by Walker et al. In Pediatrics (1990), which enrolled children with idiopathic short stature and documented both GH-stimulating efficacy and the injection-site reaction profile that became central to the label. [2]

What the Clinical Evidence Showed at Approval

Walker et al. (1990) reported that nightly subcutaneous sermorelin at 30 mcg/kg increased mean serum GH levels and produced statistically significant gains in height velocity over 12 months compared to baseline. [2] Injection-site reactions, including erythema, pain, and swelling, occurred in approximately 17% of treated children. No serious systemic adverse events were attributed to the drug during the trial period.

The FDA review team concluded that the benefit-risk profile was acceptable for the narrow pediatric indication, given that alternative rhGH products already existed and sermorelin offered a pituitary-stimulating rather than replacement approach.

Voluntary Market Withdrawal in 2008

Serono (later acquired by Merck KGaA / EMD Serono) voluntarily withdrew Geref from the US market in 2008. The withdrawal was commercial, not driven by a safety finding or FDA enforcement action. The FDA's Drugs@FDA database confirms NDA 020613 is listed as "Discontinued." [1]

This distinction between voluntary commercial withdrawal and a safety-based recall is legally significant. A voluntary withdrawal does not create a finding of danger, and it does not preclude compounding under section 503A of the Federal Food, Drug, and Cosmetic Act, provided other criteria are met.

Current US Regulatory Framework: 503A Compounding

Since 2008, the only legal US pathway for sermorelin is through 503A compounding pharmacies operating under the supervision of a licensed prescriber. The 503A framework is established in 21 U.S.C. § 353a. [3]

What 503A Allows and What It Does Not

A 503A pharmacy may compound sermorelin for an individual patient based on a valid prescription from a licensed practitioner. The pharmacy does not need FDA approval for the compounded preparation itself, but must use bulk drug substances that appear on FDA's approved bulk list for 503A pharmacies.

Sermorelin acetate was included on the 503A bulk substance list, which allowed compounding to continue after the branded product's withdrawal. Compounded sermorelin is typically dispensed as a lyophilized powder for reconstitution with bacteriostatic water, supplied in multi-dose vials with standard subcutaneous injection kits.

The 2023 503B Bulk List Exclusion

The FDA's 503B outsourcing facility framework is a separate, higher-volume compounding pathway established under DQSA 2013. In 2023, the FDA finalized its decision to exclude sermorelin from the 503B bulk substances list, meaning large-scale outsourcing facilities may no longer compound sermorelin for office stock or for distribution without individual patient prescriptions. [4] This action does not affect 503A pharmacies, but it restricts the volume pathway.

Prescribers relying on office-stocked sermorelin from 503B outsourcers should verify current supplier compliance with this rule.

Prescription Requirements and Off-Label Use

No FDA-approved indication exists for sermorelin in adults. Adult prescriptions for growth hormone optimization, body composition, or anti-aging are off-label uses of a compounded substance. Prescribers writing these orders must document the clinical rationale, obtain informed consent specific to the off-label nature, and comply with state medical board standards. The FDA guidance on off-label use notes that off-label prescribing is legal but that the prescriber bears responsibility for clinical judgment. [5]

Sermorelin Label: Key Requirements from NDA 020613

The original Geref prescribing information established labeling standards that inform how compounding pharmacies and prescribers should approach sermorelin today.

Approved Dosing in the Original Label

The Geref label specified 0.03 mg/kg (30 mcg/kg) administered subcutaneously once daily at bedtime for pediatric patients with idiopathic GH deficiency. Treatment was to be continued until satisfactory height velocity was achieved or epiphyseal fusion occurred. The label required periodic assessment of GH axis function and height velocity every six months. [1]

Compounded sermorelin for adults is prescribed at very different doses, commonly 200 to 500 mcg subcutaneously at bedtime, a range derived from clinical practice rather than approved labeling. No FDA-reviewed dose-finding studies support these adult doses.

Contraindications and Warnings in the Original Label

The Geref label listed the following contraindications and warnings:

• Hypersensitivity to sermorelin or any component of the formulation.
• Hypothyroidism: the label warned that untreated hypothyroidism may blunt the GH response to sermorelin, and thyroid function testing before and during treatment was recommended.
• Intracranial lesions: patients with active intracranial tumors were excluded, consistent with all GH-axis therapies.
• Antibody formation: the label noted that antibodies to sermorelin could develop, potentially reducing efficacy over time, though clinical significance was uncertain.

The original label did not list a boxed warning. No evidence of carcinogenicity emerged from the pre-approval dataset.

Injection-Site Reactions: The Predominant Adverse Event

Injection-site reactions remain the most commonly reported adverse event. In the Walker et al. (1990) key trial, erythema, pain, and swelling at the injection site occurred in approximately 17% of pediatric subjects. [2] Post-market case reports have documented occasional episodes of transient facial flushing and headache, consistent with the vasodilatory properties of GHRH-class peptides.

Global Regulatory Status Outside the United States

Sermorelin has no approved marketing authorization in any major non-US jurisdiction as of 2025. The table below summarizes the position by region.

European Union and EMA

The European Medicines Agency (EMA) has no published European Public Assessment Report (EPAR) for sermorelin. No marketing authorization application (MAA) has been approved for sermorelin under the centralized procedure. Individual member states could theoretically grant national authorizations, but no such authorization is publicly registered in the EMA's product database. [6]

Growth hormone deficiency in Europe is managed with approved recombinant GH products (somatropin preparations) and, for adult-onset GHD, occasionally with tesamorelin (Egrifta) in specific markets, but sermorelin itself is not among these.

United Kingdom (MHRA)

Following Brexit, the UK Medicines and Healthcare products Regulatory Agency (MHRA) maintains its own product register. Sermorelin does not appear in the UK's Product Licence database. Access for individual patients may be possible under the MHRA's Specials framework (the UK equivalent of compounding), subject to a named-patient prescription from a registered practitioner.

Canada (Health Canada)

Health Canada has not issued a Drug Identification Number (DIN) for sermorelin. The drug is not listed in Health Canada's Drug Product Database as an authorized product. [7] Canadian practitioners can access sermorelin through the Special Access Program (SAP) for individual patients with documented medical need, but this requires a formal application and Health Canada approval on a case-by-case basis.

Australia (TGA)

The Therapeutic Goods Administration (TGA) does not list sermorelin on the Australian Register of Therapeutic Goods (ARTG). Australian access is possible through the TGA's Special Access Scheme (SAS), specifically SAS Category B, which requires a physician to submit an application for a patient with a serious or life-threatening condition. [8] Compounding pharmacies in Australia operating under TGA oversight may prepare sermorelin for individual patients under SAS authorization.

Japan, South Korea, and Other Asian Markets

No regulatory approvals for sermorelin have been identified in Japan (PMDA), South Korea (MFDS), or other Asian regulatory databases as of January 2025. Growth hormone axis modulation in these markets relies primarily on approved somatropin preparations.

Post-Market Safety Record and Surveillance Data

Adverse Event Reports in FDA FAERS

The FDA Adverse Event Reporting System (FAERS) contains a modest number of reports for sermorelin, reflecting the drug's limited commercial history and the fact that compounded products are under-reported in pharmacovigilance systems. Reported events cluster around injection-site reactions, transient headache, and flushing. No fatalities have been causally attributed to sermorelin in the FAERS dataset. [9]

The low FAERS signal density should not be interpreted as a definitive safety endorsement. Compounded drugs are systematically under-reported because they lack NDC codes and are not captured in standard pharmacovigilance feeds.

IGF-1 Monitoring and the Acromegaly Concern

Because sermorelin raises GH levels, prolonged supraphysiologic stimulation theoretically carries the same risks as GH excess: insulin resistance, fluid retention, carpal tunnel syndrome, and, over decades, possible contribution to acromegalic features. No controlled long-term safety trial in adults has been completed for compounded sermorelin.

Clinical guidelines from the Endocrine Society on growth hormone deficiency recommend monitoring serum IGF-1 levels during GH-axis therapy to avoid supraphysiologic IGF-1 concentrations. [10] The same monitoring logic applies to sermorelin: an IGF-1 level above the age- and sex-adjusted normal range signals over-stimulation and warrants dose reduction or cessation.

Antibody Formation and Long-Term Efficacy

The Geref label disclosed that antibodies to sermorelin could develop during treatment. A study of pediatric patients on long-term sermorelin therapy found that antibody formation did not uniformly produce clinical resistance, but a subset of patients experienced attenuated GH response after 12 or more months of therapy. [2] Prescribers using sermorelin for more than six months should consider periodic GH-stimulation testing or IGF-1 trending to assess continued responsiveness.

The HealthRX clinical team applies a four-checkpoint framework before initiating compounded sermorelin in adult patients: (1) confirm baseline IGF-1 and GH stimulation test to establish true GH axis insufficiency; (2) rule out active intracranial pathology with pituitary MRI when clinically indicated; (3) obtain thyroid function panel and correct hypothyroidism before starting, given the label warning about blunted response; (4) set a 90-day IGF-1 recheck to titrate dose and confirm the target range of 150 to 300 ng/mL in adults aged 30 to 60. This framework operationalizes the original label warnings for the off-label adult context.

Compounding Pharmacy Quality Standards

Because compounded sermorelin carries no FDA-reviewed manufacturing oversight equivalent to an approved drug, the quality of the final preparation depends entirely on the compounding pharmacy.

USP Standards Applicable to Compounded Sermorelin

United States Pharmacopeia (USP) Chapter 797 governs sterile compounding standards, including environmental controls, beyond-use dating, and sterility testing for compounded injectables. [11] Sermorelin, as a subcutaneous injectable peptide, falls squarely under USP 797. Prescribers should verify that the compounding pharmacy they use holds a current state pharmacy board license, maintains ISO 5 cleanroom conditions, and conducts end-product sterility and potency testing.

PCAB Accreditation as a Quality Signal

The Pharmacy Compounding Accreditation Board (PCAB), a division of URAC, offers voluntary accreditation for compounding pharmacies. PCAB accreditation requires adherence to USP 795, 797, and 800 standards and includes unannounced inspections. While PCAB accreditation is not required by law, it provides an independent quality signal. Prescribers selecting a sermorelin compounding partner should request the pharmacy's PCAB or equivalent accreditation certificate.

Sermorelin vs. Other GHRH Analogs: A Regulatory Comparison

Understanding sermorelin's status requires context against related GHRH-class peptides.

Tesamorelin (Egrifta): The Approved Adult Comparator

Tesamorelin (brand name Egrifta SV, Theratechnologies) received FDA approval in 2010 (NDA 022505) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. [12] It is a full-length GHRH analog with a trans-3-hexenoic acid modification that extends half-life. Tesamorelin is the only FDA-approved GHRH-class drug for an adult indication in the United States, and its approval underscores that the GHRH receptor pathway can be targeted safely in adults when trials are conducted. Sermorelin has never undergone a comparable adult trial.

CJC-1295 and Ipamorelin: No Approved Status

CJC-1295 (a modified GHRH analog) and ipamorelin (a GH secretagogue acting via the ghrelin receptor) are frequently combined with sermorelin in compounded formulations. Neither drug holds any FDA approval, EMA authorization, or Health Canada DIN. Both are on the FDA's list of bulk substances that raise significant safety concerns, which restricts their use in 503B outsourcing and subjects 503A use to heightened scrutiny. Prescribers combining sermorelin with these agents should document the rationale carefully and be aware that the regulatory risk profile is additive.

Practical Prescribing Guidance Within the Current Regulatory Framework

Given the regulatory field described above, the following points reflect current best practice for US-based practitioners:

Patient Selection

Adult patients appropriate for compounded sermorelin typically present with low-normal or below-normal IGF-1 levels, symptoms of growth hormone insufficiency (fatigue, reduced lean mass, increased visceral adiposity), and no contraindications listed in the original Geref label. The American Association of Clinical Endocrinology (AACE) growth hormone guidelines provide a diagnostic framework for adult GH deficiency that can inform off-label sermorelin prescribing. [10]

Documentation Requirements

Because no FDA-approved labeling exists for adult sermorelin use, the prescriber's chart should include: confirmed diagnosis or clinical indication, baseline IGF-1 value with date, documentation of off-label informed consent, planned monitoring intervals, and a target IGF-1 range. State medical boards in several states, including Florida and Texas, have issued guidance on peptide prescribing that echoes these documentation standards.

Dose and Monitoring

Typical adult doses used in clinical practice range from 200 to 500 mcg subcutaneously at bedtime. No FDA-reviewed dose-ranging trial exists for adults, so dosing is titrated against IGF-1 response. A baseline IGF-1 below 100 ng/mL in a patient aged 40 to 60 supports a starting dose of 300 mcg nightly, with a recheck IGF-1 at 90 days. Doses producing IGF-1 above 350 ng/mL in this age group should be reduced, given the Endocrine Society's concern about supraphysiologic IGF-1 and potential long-term risks. [10]